CMS
Idiopathic Pulmonary Fibrosis · ANZCTR
Clinical trials
1
Mechanism
ANZCTR
Developer
Zambon SpA
Overview
CMS is an agent tracked by PF-Atlas in the context of idiopathic pulmonary fibrosis, acting via anzctr. It appears in 1 tracked IPF clinical trial.
CMS clinical trials
Explore related
Medical disclaimer. This page summarizes research about CMS for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.